Refining risk assessment in women with atypical hyperplasia

Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146–151. Carter CL, Corle DK, Micozzi MS, et al.: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988, 128:467–477. London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992, 267:941–944. Krieger N, Hiatt RA: Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992, 135:619–631. Fabian CJ, Kimler BF, Zalles CM, et al.: Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000, 2:1217–1227. Wrensch MR, Petrakis NL, Miike R, et al.: Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001, 93:1791–1798. Hartmann LC, Sellers TA, Frost MH, et al.: Benign breast disease and the risk of breast cancer. N Engl J Med 2005, 353:229–237. Page DL, Dupont WD, Rogers LW, et al.: Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 1985, 55:2698–2708. Page DL, Rogers LW: Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992, 23:1095–1097. Sloane JP, Amendoeira I, Apostolikas N, et al.: Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. Virchows Arch 1999, 434:3–10. Schnitt SJ, Connolly JL, Tavassoli FA, et al.: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992, 16:1133–1143. Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879–1886. Elmore JG, Fletcher SW: The risk of cancer risk prediction: “What is my risk of getting breast cancer?” J Natl Cancer Inst 2006, 98:1673–1675. Rockhill B, Spiegelman D, Byrne C, et al.: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001, 93:358–366. Pankratz VS, Hartmann LC, Degnim AC, et al.: Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol 2008, 26:5374–5379. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Statist Med 2004, 23:1111–1130. Amir E, Evans DG, Shenton A, et al.: Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003, 40:807–814. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371–1388. Port ER, Montgomery LL, Heerdt AS, Borgen PL: Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001, 8:580–585. Degnim AC, Visscher DW, Berman HK, et al.: Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 2007, 25:2671–2677. Collins LC, Baer HJ, Tamimi RM, et al.: The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease. Results from the Nurses’ Health Study. Cancer 2006, 107:1240–1247. Collins LC, Baer HJ, Tamimi RM, et al.: Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia. Results from the Nurses’ Health Study. Cancer 2007, 109:180–187. Marshall LM, Hunter DJ, Connolly JL, et al.: Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997, 6:297–301. Page DL, Schuyler PA, Dupont WD, et al.: Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003, 361:125–129. Dupont WD, Page DL: Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989, 21:723–725. Milanese TR, Hartmann LC, Sellers TA, et al.: Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006, 98:1600–1607. McLaren BK, Schuyler PA, Sanders ME, et al.: Excellent survival, cancer type, and Notthingham grade after atypical lobular hyperplasia on initial breast biopsy. Cancer 2006, 107:1227–1233. Moulis S, Sgroi DC: Re-evaluating early breast neoplasia. Breast Cancer Res 2008, 10:302. Ma X-J, Salunga R, Tuggle JT, et al.: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003, 100:5974–5979. Petroff BK, Phillips TA, Kimler BF, Fabian CJ: Detection of biomarker gene expression by real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed random periareolar fine needle aspirates of human breast tissue. Anal Quant Cytol Histol 2006, 28:297–302. Ristimäki A, Sivula A, Lundin J, et al.: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62:632–635. Shim V, Gauthier ML, Sudilovsky D, et al.: Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003, 63:2347–2350. Visscher DW, Pankratz VS, Santisteban M, et al.: Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 2008, 100:421–427. Gobbi H, Dupont WD, Simpson JF, et al.: Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999, 91:2096–2101. Shaaban AM, Sloane JP, West CR, Foster CS: Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 2002, 160:597–604. Khan QJ, Kimler BF, Clark J, et al.: Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev 2005, 14:786–789. Santisteban M, Reynolds C, Barr Fritcher EG, et al.: Ki67: a time varying biomarker of risk of breast cancer in atypical hyperplasia. Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 9–13, 2009. Bean GR, Bryson AD, Pilie PG, et al.: Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 2007, 13:6834–6841. Poola I, DeWitty RL, Marshalleck JJ, et al.: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005, 11:481–483. Poola I, Shokrani B, Bhatnagar R, et al.: Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res 2006, 12:4773–4783. Poola I, Abraham J, Marshalleck JJ, et al.: Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clin Cancer Res 2008, 14:1274–1280. Hojilla CV, Mohammed FF, Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003, 89:1817–1821. Lacroix M, Zammatteo N, Remacle J, Leclercq G: A low density DNA microarray for analysis of markers in breast cancer. Int J Biol Markers 2002, 17:5–23.